Analysts Set Henry Schein, Inc. (NASDAQ:HSIC) Target Price at $77.10

Henry Schein, Inc. (NASDAQ:HSIC) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $77.10.

A number of equities analysts have commented on the company. Barrington Research reduced their price objective on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Piper Sandler reissued an “overweight” rating and issued a $86.00 price objective on shares of Henry Schein in a research note on Friday, June 21st. Robert W. Baird reduced their price objective on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, Evercore ISI dropped their target price on Henry Schein from $72.00 to $70.00 and set an “in-line” rating for the company in a research report on Wednesday, August 7th.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Swedbank AB bought a new stake in Henry Schein in the first quarter valued at about $215,998,000. Boston Partners increased its holdings in Henry Schein by 144.1% in the fourth quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after purchasing an additional 1,556,831 shares during the last quarter. Norges Bank bought a new stake in Henry Schein in the fourth quarter valued at about $111,715,000. Nuance Investments LLC bought a new stake in Henry Schein in the fourth quarter valued at about $103,446,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Henry Schein in the second quarter valued at about $46,683,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of HSIC stock opened at $69.79 on Wednesday. The stock’s fifty day simple moving average is $67.71 and its 200 day simple moving average is $71.37. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.75 and a quick ratio of 1.02. The firm has a market cap of $8.94 billion, a price-to-earnings ratio of 23.58, a P/E/G ratio of 1.80 and a beta of 0.87. Henry Schein has a one year low of $60.01 and a one year high of $82.63.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.22 by $0.01. The business had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. Henry Schein’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.31 EPS. On average, analysts expect that Henry Schein will post 5.16 earnings per share for the current fiscal year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.